Education
About Us
Working with TipRanks
Follow Us
Cero Therapeutics Holdings, Inc. (CERO)
OTHER OTC:CERO
CERO Stock Chart & Stats
$0.07
-$1.53(-29.25%)
At close: 4:00 PM EST
$0.07
-$1.53(-29.25%)
Day’s Range― - ―
52-Week Range$0.04 - $63.60
Previous Close$3.66
Volume998.67K
Average Volume (3M)321.39K
Market Cap
$949.62K
Enterprise Value$5.35M
Total Cash (Recent Filing)$2.02M
Total Debt (Recent Filing)$931.02K
Price to Earnings (P/E)―
Beta-0.87
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-38.99
Shares Outstanding21,102,670
10 Day Avg. Volume493,322
30 Day Avg. Volume321,389
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-7.65
Price to Sales (P/S)0.00
P/FCF Ratio-2.50
Enterprise Value/Market Cap5.63
Enterprise Value/Revenue4.60
Enterprise Value/Gross Profit17.14
Enterprise Value/Ebitda-0.42
Forecast
1Y Price Target
$0.10Price Target Upside42.86% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-2.11
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Capital Runway And FinancingCompany reports a near-term capital runway that allows ongoing CER-1236 clinical work while positioning the program to pursue additional financing if early response data are favorable.
Clinical Safety And Dose EscalationInitial patient dosing and clearance for dose intensification in the Phase 1 study indicate an encouraging safety profile that supports continued dose escalation.
Therapeutic DifferentiationCER-1236 leverages the TIM-4 receptor to engage a natural immune-apoptosis pathway, offering a distinct mechanism compared with traditional CAR-T approaches.
Bears Say
Analyst Recommendation ChangeA downgrade from Buy to Hold reflects heightened execution and liquidity risks tied to the company’s change in listing status.
Dilution And Valuation PressureProjected dilution and adjustments to the capital structure have led analysts to cut valuation assumptions, creating downward pressure on the stock's outlook.
NASDAQ Delisting And Market AccessDelisting from NASDAQ has prompted analyst concern about reduced market visibility and weaker investor access, which can hinder liquidity and share trading.
CERo Therapeutics Holdings News
CERO FAQ
What was Cero Therapeutics Holdings, Inc.’s price range in the past 12 months?
Cero Therapeutics Holdings, Inc. lowest stock price was $0.04 and its highest was $63.60 in the past 12 months.
What is Cero Therapeutics Holdings, Inc.’s market cap?
Cero Therapeutics Holdings, Inc.’s market cap is $949.62K.
When is Cero Therapeutics Holdings, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Cero Therapeutics Holdings, Inc.’s earnings last quarter?
Currently, no data Available
Is Cero Therapeutics Holdings, Inc. overvalued?
According to Wall Street analysts Cero Therapeutics Holdings, Inc.’s price is currently Undervalued.
Does Cero Therapeutics Holdings, Inc. pay dividends?
Cero Therapeutics Holdings, Inc. does not currently pay dividends.
What is Cero Therapeutics Holdings, Inc.’s EPS estimate?
Cero Therapeutics Holdings, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cero Therapeutics Holdings, Inc. have?
Cero Therapeutics Holdings, Inc. has 21,102,670 shares outstanding.
What happened to Cero Therapeutics Holdings, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cero Therapeutics Holdings, Inc.?
Currently, no hedge funds are holding shares in CERO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cero Therapeutics Holdings, Inc.
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.
CERO Stock 12 Month Forecast
Average Price Target
$0.10
▲(42.86% Upside)
Technical Analysis
Theriva Biologics
―
GT Biopharma
―
Revelation Biosciences
―
Dermata Therapeutics
―
Psyence Biomedical
―